KAPERZOL SUBA 50mg price in UAE

Overview

Welcome to Dwaey, specifically on KAPERZOL SUBA 50mg Capsules (Hard Gelatin) page.
This medicine contains an important and useful components, as it consists of Itraconazole.
KAPERZOL SUBA 50mg is available in the market in concentration 50 mg/Capsule and in the form of Capsules (Hard Gelatin).

PHARMAX PHARMACEUTICALS FZ LLC is the producer of KAPERZOL SUBA 50mg and it is imported from UAE, The most popular alternatives of KAPERZOL SUBA 50mg are listed downward .

Mode Of Action

Itraconazole decreases ergosterol synthesis by interfering w/ cytochrome P450 activity. This inhibits cell membrane function of susceptible fungi including Microsporum spp., Trichophyton spp., Candida spp., Aspergillus spp., Epidermophyton spp., Cryptococcus neoformans, Histoplasma capsulatum, Blastomyces dermatitidis, sporothrix schenckii, Malassezia furfur, Coccidioides immitis and Paracoccidiodes brasiliensis. It also has antiprotozoal activity against Leishmania spp.

Indication

Candidiasis
Fungal infections
Tinea pedis
Tinea cruris
Tinea corporis
Pityriasis versicolor

Precaution

Renal insufficiency; CHF, history of CHF, COPD; monitor liver function. Lactation: Drug enters breast milk; weigh risk against benefit

Side Effects

>10% Nausea (11%) 1-10% Rash (9%)
Vomiting (5%)
Edema (4%)
Headache (4%)
Abnormal liver function test results (3%)
Diarrhea (3%)
Fever (3%)
Hypertension (3%)
Pruritus (3%)
Fatigue (2-3%)
Abdominal pain (2%)
Dizziness (2%)
Hypertriglyceridemia (2%)
Hypokalemia (2%)
Albuminuria (1%)
Anorexia (1%)
Decreased libido (1%)
Hepatitis (1%)
Malaise (1%) Potentially Fatal: Liver failure; heart failure; pulmonary oedema; CV disease.

Contra indication

Hypersensitivity to azole antifungals; pregnancy and lactation; hepatic disease. IV: CrCl: <30 ml/min.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

May increase the plasma concentrations of oral anticoagulants, digoxin, cilostazol, alprazolam, midazolam (IV), repaglinide, corticosteroids (e.g. budesonide, dexamethasone, fluticasone, methylprednisolone). May increase plasma concentration w/ HIV protease inhibitors (e.g. ritonavir, indinavir, saquinavir), erythromycin, clarithromycin. May reduce plasma concentration w/ isoniazid, carbamazepine, nevirapine, phenytoin, Phenobarbital, rifampicin, rifabutin. May reduce absorption w/ PPIs, antacids, antimuscarinics, histamine H2 receptor antagonists. Concomitant use w/ dihydropyridines may cause oedema. May increase negative inotropic effects of verapamil. May increase risk of potentially fatal resp depression w/ fentanyl. Potentially Fatal: May increase risk of QT prolongation or torsades de pointes w/ astemizole, bepridil, cisapride, dofetilide, levacetylmethadol (levomethadyl), mizolastine, pimozide, quinidine, sertindole, terfenadine, methadone, ranolazine, dronedarone, halofantrine. May increase risk of myopathy including rhabdomyolysis w/ HMG-CoA reductase inhibitors (e.g. atorvastatin, lovastatin, simvastatin). May increase risk of ergotism w/ ergot alkaloids (e.g. ergotamine, dihydroergotamine, ergometrine, methylergometrine). May potentiate hypnotic and sedative effect of triazolam and oral midazolam. May increase plasma concentration of eletriptan, nisoldipine, felodipine, disopyramide, irinotecan, lurasidone; colchicine (patient w/ renal or hepatic failure). May increase risk of hypotension and hyperkalaemia w/ eplerenone.